Dusseldorf - Delayed Quote EUR

Seres Therapeutics Inc (1S9.DU)

0.0000

(0.00%)

At close: April 17 at 7:30:21 PM GMT+2

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intes

GlobeNewswire 2 days ago

MCRB
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, p

GlobeNewswire 8 days ago

MCRB
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 14 days ago

MCRB
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?

With the business potentially at an important milestone, we thought we'd take a closer look at Seres Therapeutics...

Simply Wall St. last month

MCRB
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...

Seres Therapeutics Inc (MCRB) reports reduced net loss and strategic advancements in SER-155, while addressing ongoing challenges in clinical development.

GuruFocus.com last month

MCRB
Q4 2024 Seres Therapeutics Inc Earnings Call

Q4 2024 Seres Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

MCRB
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (7

GlobeNewswire last month

MCRB
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join t

GlobeNewswire last month

MCRB
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed protocol for the next SER-155 study in allo-HSCT, which the Company anticipates submitting to FDA in Q2 CAMBRIDGE, Mass., March 03, 20

GlobeNewswire last month

MCRB
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As

GlobeNewswire 3 months ago

MCRB
Seres announces new translational biomarker results from SER-155 Phase 1b study

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation. “Following SER-155 administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and immune homeostasis, in both cases as compared to placebo. These resu

TipRanks 3 months ago

MCRB
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres’ live biotherapeutics to target inflammatory and immune diseases SER-155 clinical results accepted for 2025 TANDEM Meeting oral presentation in Best Abstracts in Infectious Diseases New SER-155 payer resear

GlobeNewswire 3 months ago

MCRB
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

It's not possible to invest over long periods without making some bad investments. But really big losses can really...

Simply Wall St. 4 months ago

MCRB
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and CEO, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing all

TipRanks 4 months ago

MCRB
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently

GlobeNewswire 4 months ago

MCRB
Seres’ SER-155 gains breakthrough status for BSIs reduction

A live biotherapeutic, SER-155 secured fast track status from the FDA in December 2023.

Pharmaceutical Technology 4 months ago

MCRB
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025 Seres seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the C

GlobeNewswire 4 months ago

MCRB
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at www.seresther

GlobeNewswire 5 months ago

MCRB
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Seres Therapeutics ( NASDAQ:MCRB ) Third Quarter 2024 Results Key Financial Results Net loss: US$51.0m (loss widened by...

Simply Wall St. 5 months ago

MCRB
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased net losses and operational uncertainties.

GuruFocus.com 5 months ago

MCRB

Performance Overview

Return	1S9.DU	S&P 500 (^GSPC)
YTD	-100.00%	-4.18%
1-Year	-100.00%	+12.30%
3-Year	-100.00%	+36.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Seres Therapeutics Inc (1S9.DU)

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...

Q4 2024 Seres Therapeutics Inc Earnings Call

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres announces new translational biomarker results from SER-155 Phase 1b study

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres’ SER-155 gains breakthrough status for BSIs reduction

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

Performance Overview